The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Probing the Probes: Fitness Factors For Small Molecule Tools
Open accessAbstract
Chemical probes for interrogating biological processes are of considerable current interest. Cell permeable small molecule tools have a major role in facilitating the functional annotation of the human genome, understanding both physiological and pathological processes, and validating new molecular targets. To be valuable, chemical tools must satisfy necessary criteria and recent publications have suggested objective guidelines for what makes a useful chemical probe. Although recognizing that such guidelines may be valuable, we caution against overly restrictive rules that may stifle innovation in favor of a "fit-for-purpose" approach. Reviewing the literature and providing examples from the cancer field, we recommend a series of "fitness factors" to be considered when assessing chemical probes. We hope this will encourage innovative chemical biology research while minimizing the generation of poor quality and misleading biological data, thus increasing understanding of the particular biological area, to the benefit of basic research and drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
The genome of the blood fluke Schistosoma mansoni
Berriman, M., Haas, B. J., LoVerde, P. T., Wilson, R. A., Dillon, G. P., Cerqueira, G. C., Mashiyama, S. T., Al-Lazikani, B., Andrade, L. F., Ashton, P. D., et al. (2009) · Nature · doi:10.1038/nature08160 · Cited by 1,058
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
A chemical switch for inhibitor-sensitive alleles of any protein kinase
Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., et al. (2000) · Nature · doi:10.1038/35030148 · Cited by 1,031
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Dobson, C. M. (2004) · Nature · doi:10.1038/nature03192 · Cited by 1,003
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization
Kerns, E. H., & Di, L. (2016) · Cited by 784
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Self-citationControl of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
The Practice of Medicinal Chemistry
(2003) · Elsevier eBooks · doi:10.1016/b978-0-12-744481-9.x5000-4 · Cited by 702
Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D., & Panayotou, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1722 · Cited by 682
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
High-throughput screening assays for the identification of chemical probes
Inglese, J., Johnson, R. L., Simeonov, A., Xia, M., Zheng, W., Austin, C. P., & Auld, D. S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.17 · Cited by 614
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
Gazit, A., Yaish, P., Gilon, C., & Levitzki, A. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a020 · Cited by 600
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors
Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988) · Science · doi:10.1126/science.3263702 · Cited by 587
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Self-citationWORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationDiscovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494
Wohnsland, F., & Faller, B. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001020e · Cited by 492
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Self-citationEccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Self-citationCritical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Self-citationNew Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 439
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Chemical genetics resulting from a passion for synthetic organic chemistry
Schreiber, S. L. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00126-6 · Cited by 410
Duncia, J. V., Santella, J. B., Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J.-H., Earl, R. A., Tabaka, A. C., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00522-8 · Cited by 401
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Self-citationNonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Self-citationG2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
Bucher, N., & Britten, C. D. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604208 · Cited by 349
NIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H., Neel, D. A., Rito, C. J., Singh, U., Stramm, L. E., Melikian-Badalian, A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950588y · Cited by 339
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Self-citationThe p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Berndt, A., Miller, S., Williams, O., Le, D. D., Houseman, B. T., Pacold, J. I., Gorrec, F., Hon, W.-C., Ren, P., Liu, Y., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.293 · Cited by 292
Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34
Miller, S., Tavshanjian, B., Oleksy, A., Perisic, O., Houseman, B. T., Shokat, K. M., & Williams, R. L. (2010) · Science · doi:10.1126/science.1184429 · Cited by 287
Heat Shock Protein 90: Inhibitors in Clinical Trials
Biamonte, M. A., Van de Water, R., Arndt, J. W., Scannevin, R. H., Perret, D., & Lee, W.-C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9004708 · Cited by 285
Recognizing and exploiting differences between RNAi and small-molecule inhibitors
Weiss, W. A., Taylor, S. S., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio1207-739 · Cited by 283
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Self-citationRaynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Self-citationDrugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
Self-citationBenson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Self-citationLiu, T.-J., Koul, D., LaFortune, T., Tiao, N., Shen, R. J., Maira, S.-M., Garcia-Echevrria, C., & Yung, W. K. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0160 · Cited by 253
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Collins, F. (2010) · Nature · doi:10.1038/464674a · Cited by 247
PERSPECTIVE: THE SMALL-MOLECULE APPROACH TO BIOLOGY
SCHREIBER (2003) · Chemical & Engineering News Archive · doi:10.1021/cen-v081n009.p051 · Cited by 246
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
COLLINS, I., & GARRETT, M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.009 · Cited by 220
Self-citationCheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Self-citationChemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine
Nakano, H., & Ōmura, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.4 · Cited by 203
Rationalizing the chemical space of protein–protein interaction inhibitors
Sperandio, O., Reynès, C. H., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.007 · Cited by 202
Measuring and interpreting the selectivity of protein kinase inhibitors
Smyth, L. A., & Collins, I. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0023-9 · Cited by 197
Self-citationWhittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0110 · Cited by 195
Self-citationHuang, K. H., Veal, J. M., Fadden, R. P., Rice, J. W., Eaves, J., Strachan, J.-P., Barabasz, A. F., Foley, B. E., Barta, T. E., Ma, W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900230j · Cited by 192
Clarke, P. A., te Poele, R., Wooster, R., & Workman, P. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00785-7 · Cited by 184
Self-citationTargeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?
Powers, M. V., Jones, K., Barillari, C., Westwood, I., Montfort, R. L. M. V., & Workman, P. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11204 · Cited by 179
Self-citationTargeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90
Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P., & Chiosis, G. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.008 · Cited by 171
Physicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 167
Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.032 · Cited by 162
Self-citationGatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Whittaker, S. R., Kirk, R., Hayward, R., Zambon, A., Virós, A., Cantariño, N., Affolter, A., Nourry, A., Niculescu‐Duvaz, D., Springer, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000758 · Cited by 158
Workman, P. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455279 · Cited by 150
Self-citationOpen access chemical and clinical probes to support drug discovery
Edwards, A. M., Bountra, C., Kerr, R. S., & Willson, T. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-436 · Cited by 140
Maloney, A., Clarke, P. A., Naaby‐Hansen, S., Stein, R. C., Koopman, J.-O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2968 · Cited by 140
Self-citationBaggiolini, M., Dewald, B., Schnyder, J., Ruch, W., Cooper, P. H., & Payne, T. G. (1987) · Experimental Cell Research · doi:10.1016/0014-4827(87)90201-1 · Cited by 140
Wagner, J., von Matt, P., Sedrani, R. C., Albert, R., Cooke, N. G., Ehrhardt, C., Geiser, M., Rummel, G., Stark, W., Strauss, A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901108b · Cited by 132
Kasibhatla, S. R., Hong, K., Biamonte, M. A., Busch, D. J., Karjian, P. L., Sensintaffar, J., Kamal, A., Lough, R. E., Brekken, J., Lundgren, K., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm050752+ · Cited by 126
Small molecule modulators of cyclin-dependent kinases for cancer therapy
Senderowicz, A. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204085 · Cited by 124
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Bao, R., Lai, C.-J., Qu, H., Wang, D.-G., Yin, L., Zifcak, B. M., Atoyan, R., Wang, J., Samson, M., Forrester, J. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0152 · Cited by 116
Lead-like, drug-like or “Pub-like”: how different are they?
Oprea, T. I., Allu, T. K., Fara, D. C., Curpan, R. F., Ostopovici, L., & Bologa, C. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9105-3 · Cited by 114
Eyers, P. A., van den IJssel, P., Quinlan, R. A., Goedert, M., & Cohen, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00552-9 · Cited by 113
Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology
Fuse, E., Kuwabara, T., Sparreboom, A., Sausville, E. A., & Figg, W. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274549 · Cited by 113
Sharp, S. Y., Boxall, K. J., Rowlands, M., Prodromou, C., Roe, S. M., Maloney, A., Powers, M. V., Clarke, P. A., Box, G., Sanderson, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3473 · Cited by 112
Self-citationA crowdsourcing evaluation of the NIH chemical probes
Oprea, T. I., Bologa, C., Boyer, S. K., Curpan, R. F., Glen, R. C., Hopkins, A. L., Lipinski, C. A., Marshall, G. R., Martin, Y. C., Halip, L., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-441 · Cited by 111
Components of Successful Lead Generation
Davis, A., Keeling, D., Steele, J., Tomkinson, N. P., & Tinker, A. C. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053828411 · Cited by 110
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. D. H., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0938 · Cited by 110
Self-citationTanramluk, D., Schreyer, A. M., Pitt, W. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00832.x · Cited by 101
Protein kinase C intervention—the state of play
Roffey, J., Rossé, C., Linch, M. D., Hibbert, A. P., McDonald, N. Q., & Parker, P. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.019 · Cited by 99
HTS and hit finding in academia – from chemical genomics to drug discovery
Frearson, J. A., & Collie, I. T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.004 · Cited by 91
Therapeutic strategies for inhibiting oncogenic BRAF signaling
Halilovic, E., & Solit, D. B. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.014 · Cited by 82
Akinaga, S., Sugiyama, K., & Akiyama, T. (2000) · PubMed · Cited by 78
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
Guillard, S., Clarke, P. A., Poele, R. T., Mohri, Z., Bjerke, L. M., Valenti, M. R., Raynaud, F. I., Eccles, S. A., & Workman, P. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7643 · Cited by 77
Self-citationInhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide
Jiang, X., Zhao, B., Britton, R., Lim, L. Y., Leong, D., Sanghera, J. S., Zhou, B. S., Piers, E., Andersen, R. J., & Roberge, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1221.3.10 · Cited by 75
Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics
Tolliday, N. J., Clemons, P. A., Ferraiolo, P., Koehler, A. N., Lewis, T. A., Li, X., Schreiber, S. L., Gerhard, D. S., & Eliasof, S. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2552 · Cited by 71
Cherrin, C., Haskell, K., Howell, B., Jones, R., Leander, K. R., Robinson, R., Watkins, A., Bilodeau, M. T., HOFFMAN, J. M. J., Sanderson, P. E. J., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11100 · Cited by 64
Cohen, P. (2009) · Biochemical Journal · doi:10.1042/bj20091428 · Cited by 64
Golub, T. R. (2010) · Nature · doi:10.1038/464679a · Cited by 62
A chemical approach to stem cell biology
Emre, N., Coleman, R., & Ding, S. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.04.024 · Cited by 54
Acquisition of Inhibitor-Sensitive Protein Kinases through Protein Design
Bishop, A. C., & Shokat, K. M. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00060-6 · Cited by 51
Building a Pharmacological Lexicon: Small Molecule Discovery in Academia
Lazo, J. S., Brady, L. S., & Dingledine, R. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035113 · Cited by 51
Soltoff, S. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305396200 · Cited by 39
The completed human genome: implications for chemical biology
Austin, C. P. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00083-8 · Cited by 35
Huryn, D. M., & Cosford, N. D. P. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42026-7 · Cited by 28
Micrometastases + Math = Model of Breast Cancer Dormancy
Hansel, D. E. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001332 · Cited by 28
Industrial-Style Screening Meets Academic Biology
Kaiser, J. (2008) · Science · doi:10.1126/science.321.5890.764 · Cited by 24
Compound Properties and Drug Quality
Lipinski, C. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00022-6 · Cited by 23
Shuttleworth, S., Silva, F., Tomassi, C., Cecil, A., Hill, T., Rogers, H., & Townsend, P. A. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04803-6 · Cited by 16
Using ChemBank to Probe Chemical Biology
Seiler, K. P., Kuehn, H., Happ, M. P., DeCaprio, D., & Clemons, P. A. (2008) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1405s22 · Cited by 8
High throughput drug profiling
Entzeroth, M., Chapelain, B., Guilbert, J., & Hamon, V. (2000) · Journal of Analytical Methods in Chemistry · doi:10.1155/s1463924600000304 · Cited by 7
(2010) · Nature Chemical Biology · doi:10.1038/nchembio.330 · Cited by 6
Cited by
The Essential Medicinal Chemistry of Curcumin
Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00975 · Cited by 1,956
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Self-citationThe promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Self-citationCellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation
Lu, Y., Li, Z., Zhang, S., Zhang, T., Liu, Y., & Zhang, L. (2023) · Theranostics · doi:10.7150/thno.79876 · Cited by 685
Metadata
- Authors
- Workman, P., & Collins, I.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 17
- Issue
- 6
- Pages
- 561-577
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2166594615
- Cited by
- 299
- References
- 146
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.